Birketts advises on sale of Real Regulatory Limited to tranScrip
14 April 2022
Birketts has advised the owner of Real Regulatory Limited on its sale to life sciences consultancy firm tranScrip for an undisclosed sum.
Real Regulatory is headquartered in Dublin and has offices in Malta and Ely, Cambridgeshire. The business has operated for more than 20 years, specialising in European regulatory affairs, quality systems and compliance for products including medicines, medical devices and drug device combinations. Managing Director Karen Real also brings more than 35 years’ experience in the pharmaceutical industry to the business and will continue in her role as Managing Director at Real Regulatory following the acquisition.
tranScrip, backed by Palatine Private Equity’s Impact Fund, is a leading contract drug developer, working with more than 250 companies since their inception in 2008. Their pharmaceutical experts provide a wide range of services and hands-on support to their clients to maximise the chance of their project’s success. Their expertise include rapid due diligence exercise, designing complex development programmes and defending regulatory submissions across various therapy areas.
Speaking after the deal, Karen Real said: “tranScrip’s work in the sector speaks for itself. This acquisition secures a bright future for both our companies and I am excited to join their team. My thanks to Nick and all those at Birketts who advised on this deal – when conducting cross-border work such as this it’s important to have experts on hand to guide you, and that’s exactly what we had.”
Nick Burt added: “The strengths of Real Regulatory and tranScrip will complement one another very well. Karen was a pleasure to work with and we look forward to seeing both businesses grow in the future.”
The content of this article is for general information only. It is not, and should not be taken as, legal advice. If you require any further information in relation to this article please contact the author in the first instance. Law covered as at April 2022.